Various international studies are bringing new visions about how to treat and perform patient management for patients with COVID-19 once they are admitted to hospital.
One of the main complications that makes treatment difficult is the formation of thrombi or clots in the blood that can cause potentially life-threatening events. According to a study conducted in the United States on more than 2,700 patients and directed by Dr. Valentí Fuster, people who are hospitalized with COVID-19 and treated with anticoagulants had a 50% greater possibility of survival and 30% less possibility of intubation.
The antiviral drug remdesivir has also shown to be more effective against COVID-19 if it is administered to seriously ill patients before they require mechanical ventilation, according to an international study of more than 1,000 patients with coronavirus. In Spain, this study was coordinated from the Infectious Diseases Service of Germans Trias i Pujol Hospital, and directed by Dr. Bonaventura Clotet.
There is also evidence that convalescent plasma, dexamethasone, ivermectin and oleandrin are successful in treating COVID-19 patients. What other developments in terms of treatments are now available for patients in different stages of the illness? Can we look forward to better expectations of a cure and a lower mortality rate in the coming months, thanks to these new treatments?
Speakers:
-
Dr. Bonaventura Clotet, Director of IrsiCaixa and Chief of the Servei de Malalties Infeccioses de l'Hospital Germans Trias i Pujol de Badalona.
-
Dr. Valentín Fuster, CNIC Director General, Director of the Cardiovascular Institute and “Physician-in-Chief” of the Mount Sinai Medical Center of Nueva York.
Moderator:
-
Josep Corbella, LA VANGUARDIA journalist specialized in science and health.
